DB-1317 / DualityBio - LARVOL DELTA

A Phase 1a/1b, first-in-human study of an ADC targeting ADAM9 (DB-1317) in participants with selected advanced or metastatic solid tumors (AACR 2026) - P1 | "Dose levels used in phase 1b part will be determined by sponsor and SMC based on phase 1a data. As of Dec 24, 2025, 7 participants have been enrolled in Australia and the United States."

ADC • First-in-human • Metastases • P1 data • Biliary Cancer • Castration-Resistant Prostate Cancer • Cholangiocarcinoma • Colorectal Cancer • Gastric Cancer • Genito-urinary Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Ductal Adenocarcinoma • Prostate Cancer • Solid Tumor • ADAM9

DB-1317, a novel ADAM9-targeting antibody-drug conjugate, exhibits potent antitumor activity against multiple gastrointestinal cancers (AACR-NCI-EORTC 2025) - "DB-1317 demonstrated promising antitumor activities across various gastrointestinal cancers, with favorable PK and safety profiles."

Colorectal Cancer • Gastric Cancer • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Solid Tumor • ADAM9

DB-1317-101: A Study of DB-1317 in Selected Advanced/Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=233 | Recruiting | Sponsor: DualityBio Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • First-in-human • Colorectal Cancer • Oncology • Solid Tumor

A Study of DB-1317 in Selected Advanced/Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=183 | Not yet recruiting | Sponsor: DualityBio Inc.

New P1 trial • Colorectal Cancer • Oncology • Solid Tumor